Skip to main content
Fig. 7 | Journal of Hematology & Oncology

Fig. 7

From: Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

Fig. 7

Mean blood counts over time in the ruxolitinib randomized and ruxolitinib crossover groups. Blood counts were based on measurements of a hemoglobin level, b platelet counts, and c white blood cell counts. *For patients in the ruxolitinib crossover group, BL represents the date of crossover to ruxolitinib. BL, baseline

Back to article page